Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

BETH ISRAEL DEACONESS MEDICAL CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1896-01-01

Employees: -

Market Cap: -

Website: https://www.bidmc.org/

Clinical Trials

Diagnostic Challenges in IC (and Male CPPS)

Completed

Conditions: Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Cystitis, Interstitial
Asymptomatic Inflammatory Prostatitis
Painful Bladder Syndrome
Chronic Bacterial Prostatitis

Interventions: Genetic: Genomic and proteomic biomarker discovery

First Posted Date: 2008-05-06

Last Posted Date: 2020-08-04

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 1000

Registration Number: NCT00672087

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders

Phase 2

Completed

Conditions: MDS
AML
APLASTIC ANEMIA
MULTIPLE MYELOMA
MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
ALL
RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA
CML Chronic Phase, Accelerated Phase, or Blast Crisis
CLL

Interventions: Drug: Cyclophosphamide
Drug: fludarabine
Drug: cyclosporine
Drug: methotrexate
Biological: G-CSF

First Posted Date: 2008-03-17

Last Posted Date: 2017-04-06

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 25

Registration Number: NCT00636909

In Vitro Expanded Autologous Invariant Natural Killer Cells in Cancer

Phase 1

Completed

Conditions: Malignant Melanoma

Interventions: Biological: INKT
Drug: GM-CSF

First Posted Date: 2008-03-07

Last Posted Date: 2017-06-09

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 9

Registration Number: NCT00631072

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma

Phase 1

Completed

Conditions: Metastatic Melanoma

First Posted Date: 2008-02-29

Last Posted Date: 2017-03-28

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 20

Registration Number: NCT00626860

Locations: 🇺🇸
BIDMC, Boston, Massachusetts, United States

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

Phase 1

Completed

Conditions: Renal Cell Carcinoma

First Posted Date: 2008-02-28

Last Posted Date: 2017-03-28

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 40

Registration Number: NCT00625755

Locations: 🇺🇸
BIDMC, Boston, Massachusetts, United States

Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12

Phase 1

Terminated

Conditions: Breast Cancer

Interventions: Biological: Dendritic Cell/Tumor Fusion Vaccine
Drug: Interleukin-12

First Posted Date: 2008-02-25

Last Posted Date: 2017-11-14

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 8

Registration Number: NCT00622401

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Electrical Impedance Myography as an Outcome Measure in Amyotrophic Lateral Sclerosis Clinical Trials

Completed

Conditions: Amyotrophic Lateral Sclerosis

First Posted Date: 2008-02-21

Last Posted Date: 2014-09-25

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 89

Registration Number: NCT00620698

Locations: 🇺🇸
Wake Forest University Baptist Medical Center, Winston-Salem, North Carolina, United States
🇺🇸
University of Virginia Medical Center, Charlottesville, Virginia, United States
🇺🇸
University of Miami Miller School of Medicine, Miami, Florida, United States

and more 5 locations

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

Completed

Conditions: Epilepsy

Interventions: Drug: Lamotrigine
Other: No Intervention
Drug: Levetiracetam
Drug: Carbamazepine

First Posted Date: 2008-02-11

Last Posted Date: 2018-10-26

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 80

Registration Number: NCT00612235

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States

RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma

Not Applicable

Withdrawn

Conditions: Renal Cell Carcinoma

First Posted Date: 2008-01-25

Last Posted Date: 2013-02-27

Lead Sponsor: Beth Israel Deaconess Medical Center

Registration Number: NCT00601120

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage

Phase 1

Completed

Conditions: Intracerebral Hemorrhage

Interventions: Drug: Deferoxamine Mesylate

First Posted Date: 2008-01-22

Last Posted Date: 2018-01-16

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 20

Registration Number: NCT00598572

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy